UK markets open in 6 hours 12 minutes

Syros Pharmaceuticals, Inc. (0LC7.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
6.27-0.43 (-6.36%)
At close: 07:03PM BST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.53
52-week change 3121.67%
S&P500 52-week change 320.87%
52-week high 38.10
52-week low 32.27
50-day moving average 36.98
200-day moving average 34.85

Share statistics

Avg vol (3-month) 3817
Avg vol (10-day) 3813
Shares outstanding 5N/A
Implied shares outstanding 6N/A
Float 812.57M
% held by insiders 11.44%
% held by institutions 182.77%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 20.1:1
Last split date 319 Sept 2022

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin 0.00%
Operating margin (ttm)-1,778.97%

Management effectiveness

Return on assets (ttm)-45.66%
Return on equity (ttm)-237.24%

Income statement

Revenue (ttm)6.98M
Revenue per share (ttm)0.22
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -122.26M
Net income avi to common (ttm)-144.49M
Diluted EPS (ttm)-1.55
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)108.3M
Total cash per share (mrq)4.05
Total debt (mrq)61.67M
Total debt/equity (mrq)409.58%
Current ratio (mrq)3.01
Book value per share (mrq)0.56

Cash flow statement

Operating cash flow (ttm)-103.9M
Levered free cash flow (ttm)-61.12M